花旗发表报告指出，随着DeepSeek推动科技热潮，内地在线医疗股今年以来显著上升。从基本面而言，该行预期人工智能(AI)能将有助于提高在线医疗公司的营运效率，预期随着经营利润率的扩张，在线医疗股的目标价将有进一步的上升空间。
该行认为，相对于美国同业的今明两年预测市销率各为18倍及13.6倍，内地医疗保健AI概念股相对便宜，预测市销率各为5倍及4.2倍，而在线医疗(如在线零售药店)及医疗保健AI(如软件供应商)股的预测市销率各为5.4倍及4.5倍。
当中，该行偏好阿里健康(00241.HK) 及医渡科技(02158.HK) ，均予以“买入”评级，另维持对阿里健康目标价9.5元，并将医渡科技的目标价由8元上调至12元。(jl/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-17 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.